Support 100 years of independent journalism.

  1. Science & Tech
  2. Coronavirus
18 May 2020updated 06 Oct 2020 9:45am

EU moves to approve Ebola drug for coronavirus

By Samir Jeraj

The European Union is expected to the drug remdesivir as a treatment for COVID-19. Such a move would make it the first treatment authorised for the coronavirus.

The head of the European Medicines Agency (EMA), Guido Rasi said during a hearing at the European parliament earlier today that “a conditional market authorisation” could be issued in “the coming day”. A week earlier the EMA recommended “compassionate use” of remdesivir for patients with severe COVID‑19, meaning it could be administered to patients even without authorisation.

The remdesivir drug is being developed by the US-based company Gilead Sciences. The conditional authorisation would allow the drug to be sold in the European Union for a year, without meeting the usual threshold for evidence on its side-effects or effectiveness.

Select and enter your email address Quick and essential guide to domestic and global politics from the New Statesman's politics team. A weekly newsletter helping you fit together the pieces of the global economic slowdown. The New Statesman’s global affairs newsletter, every Monday and Friday. The best of the New Statesman, delivered to your inbox every weekday morning. The New Statesman’s weekly environment email on the politics, business and culture of the climate and nature crises - in your inbox every Thursday. Our weekly culture newsletter – from books and art to pop culture and memes – sent every Friday. A weekly round-up of some of the best articles featured in the most recent issue of the New Statesman, sent each Saturday. A newsletter showcasing the finest writing from the ideas section and the NS archive, covering political ideas, philosophy, criticism and intellectual history - sent every Wednesday. Sign up to receive information regarding NS events, subscription offers & product updates.
  • Administration / Office
  • Arts and Culture
  • Board Member
  • Business / Corporate Services
  • Client / Customer Services
  • Communications
  • Construction, Works, Engineering
  • Education, Curriculum and Teaching
  • Environment, Conservation and NRM
  • Facility / Grounds Management and Maintenance
  • Finance Management
  • Health - Medical and Nursing Management
  • HR, Training and Organisational Development
  • Information and Communications Technology
  • Information Services, Statistics, Records, Archives
  • Infrastructure Management - Transport, Utilities
  • Legal Officers and Practitioners
  • Librarians and Library Management
  • Management
  • Marketing
  • OH&S, Risk Management
  • Operations Management
  • Planning, Policy, Strategy
  • Printing, Design, Publishing, Web
  • Projects, Programs and Advisors
  • Property, Assets and Fleet Management
  • Public Relations and Media
  • Purchasing and Procurement
  • Quality Management
  • Science and Technical Research and Development
  • Security and Law Enforcement
  • Service Delivery
  • Sport and Recreation
  • Travel, Accommodation, Tourism
  • Wellbeing, Community / Social Services
I consent to New Statesman Media Group collecting my details provided via this form in accordance with the Privacy Policy

Content from our partners
Why ports are the gateway to growth
We are living longer than our predecessors – policy must catch up
Getting Britain building